Ipamorelin
Ipamorelin is a growth hormone releasing peptide that acts through ghrelin/GHS receptor signaling to stimulate growth hormone secretion. Its clinical relevance is mostly exposure and GH-response modeling, so ProtoComp treats it as a GH-axis signal with limited direct outcome evidence.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Pharmaceutical research · 1999 · PMID 10496658
Bell-shaped dose-response — more is not better. Split into 1-3 doses.
8 weeks on, 2-4 weeks off. No PCT required.
Off-cycle: 3 weeks
2x daily (AM + PM) during 8-week cycle
Common side effects
- • Headache
- • Water retention
- • Mild hunger
- • Injection site irritation
Pregnancy / breastfeeding
No data — consult clinician
Female
Women may start at lower end of dose range. Similar GH response without sex-based variance in cortisol/prolactin.
- Does not elevate cortisol or prolactin — selective GH release
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.